Effectiveness of dupilumab for eosinophilic chronic rhinosinusitis: A single-centre study

DOI
  • Takakura Sonoka
    Department of Otolaryngology Head and Neck Surgery, Oita University Faculty of Medicine
  • Kadowaki Yoshinori
    Department of Otolaryngology Head and Neck Surgery, Oita University Faculty of Medicine
  • Tateyama Kaori
    Department of Otolaryngology Head and Neck Surgery, Oita University Faculty of Medicine
  • Hirano Takashi
    Department of Otolaryngology Head and Neck Surgery, Oita University Faculty of Medicine
  • Suzuki Masashi
    Department of Otolaryngology Head and Neck Surgery, Oita University Faculty of Medicine

Bibliographic Information

Other Title
  • 好酸球性副鼻腔炎に対するデュピルマブ使用効果の検討

Search this article

Abstract

<p>Eosinophilic chronic rhinosinusitis (ECRS) is considered an intractable disease with a high recurrence rate. Dupilumab, an antiinterleukin-4/13 monoclonal antibody was introduced in Japan in March, 2020 as a novel agent for ECRS management. We prospectively investigated the effectiveness of dupilumab for ECRS treatment. The study included eight patients (mean age, 50.1 years) with severe ECRS based on the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis study scores. Nasal polyps, nasal obstruction, smell disorder, and the 22-item sinonasal outcome test scores were recorded at baseline and at 4, 12, and 24 weeks. The Lund-Mackay computed tomography score and ratio of eosinophils in peripheral blood were also recorded at baseline and at 24 weeks, in addition to complications and treatment with or without systemic corticosteroid administration. We observed that all evaluated parameters except the ratio of eosinophils significantly improved from baseline levels across all time-points. Furthermore, dupilumab was associated with minor complications and led to a decrease in the number of patients who required oral corticosteroid therapy. In conclusion, dupilumab was highly effective against the subjective symptoms and local findings in patients with ECRS and enabled a reduction in the systemic steroid dose.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top